CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
CureVac

BRIEF

published on 11/12/2024 at 13:05, 9 days ago

CureVac Reports Q3 Financial Results and Business Updates for 2024

Financial Results MRNA Technology Strategic Restructuring GSK Collaboration Oncology Development
PRESS RELEASE

published on 11/12/2024 at 13:00, 9 days ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
CureVac announces financial results for the third quarter of 2024, including strengthened cash position, new oncology and prophylactic vaccine programs, workforce reduction, and new CFO appointment

Financial Results Oncology CureVac Prophylactic Vaccines Workforce Reduction
BRIEF

published on 11/07/2024 at 13:05, 14 days ago

CureVac Announces Upcoming Financial Results and Business Update

Financial Results Conference Call Business Update MRNA Technology CureVac
PRESS RELEASE

published on 11/07/2024 at 13:00, 14 days ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
CureVac to report financial results for Third Quarter and First Nine Months 2024 on November 12, 2024. Learn about the business update in the upcoming webcast

Financial Results Business Update MRNA Technology Q3 2024 CureVac
BRIEF

published on 11/04/2024 at 13:08, 17 days ago

CureVac Appoints Axel Sven Malkomes as CFO

Chief Financial Officer Biopharmaceutical MRNA Technology CureVac Axel Sven Malkomes
BRIEF

published on 11/04/2024 at 13:05, 17 days ago

CureVac to Showcase Data at 12th International mRNA Health Conference

Oncology Cancer Vaccine CureVac MRNA Health Conference LNP Delivery
PRESS RELEASE

published on 11/04/2024 at 13:03, 17 days ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 17 days ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 24 days ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 24 days ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer

1 2 ... 8

Accesswire

Published on 11/21/2024 at 13:30, 23 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 23 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 53 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 53 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 53 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 38 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 18 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 38 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 46 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 53 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 55 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 33 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 8 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 8 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE